Physician profile
Cheunju Chen
NPI 1538204219
$4,438.46
in general payments reported to CMS, 2019-2025
49 companies · $412 in 2025
The $412 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,335 · 2020: $1,408 · 2021: $534 · 2022: $344 · 2023: $240 · 2024: $166 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $422 · Food and Beverage: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $422.41 |
| Food and Beverage | $395.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $515.03 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $465.07 | 2019-2024 | Ultomiris, Soliris |
| Amgen INC. | $418.41 | 2019-2024 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $363.41 | 2019-2025 | |
| Abbvie INC. | $293.00 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $283.34 | 2019-2021 | |
| Allergan, INC. | $282.03 | 2019-2021 | |
| Lilly USA, LLC | $142.84 | 2019-2023 | Reyvow, Emgality |
| Csl Behring | $109.58 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $94.10 | 2020 | |
| Mallinckrodt Enterprises LLC | $91.05 | 2019 | |
| Aerin Medical INC. | $90.57 | 2025 | |
| Eisai INC. | $80.01 | 2020-2021 | |
| Genzyme Corporation | $70.40 | 2019-2022 | |
| Acorda Therapeutics, INC | $69.28 | 2019-2020 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheunju Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.